13F Holdings
中文EN

OMER OMEROS CORP

Pharmaceutical Preparations · Nasdaq · SEC CIK 1285819 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY181.2%
TTM EPS YoY176.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR70.1%

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA45.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets136.3%
Debt / equity—
Current ratio2.27x
Interest coverage-1.47x

Cash quality & payout

Operating cash flow / net income-0.38x
Accruals ratio62.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$81.30M$119.52M$114.87M$112.72M$118.78M
SG&A expense$41.50M$47.43M$49.66M$50.67M$54.84M
Operating income-$122.80M-$166.95M-$164.53M-$163.39M-$173.62M
Interest expense-$960,000$24.68M$30.84M$22.70M$19.67M
Pretax income-$2.80M-$180.32M-$174.92M-$182.03M-$191.55M
Income tax$2.01M$2.31M$0$0$0
Net income-$3.35M-$156.81M-$117.81M$47.42M$194.24M
EBITDA-$121.83M-$166.00M-$163.61M-$162.44M-$172.23M
EPS (basic)-0.05-2.70-1.880.763.12
EPS (diluted)-0.05-2.70-1.880.763.12
Weighted avg. shares (diluted)———62.74M62.34M
Balance sheet
Cash & equivalents$9.66M$3.40M$7.11M$11.01M$100.81M
Short-term investments$162.14M$86.73M$164.74M$183.91M$56.46M
Receivables$0$7.74M$8.10M$213.22M$38.16M
Inventory$0————
Current assets$215.67M$134.12M$217.90M$443.24M$247.96M
PP&E, net$1.77M$2.68M$1.95M$1.49M$1.73M
Total assets$325.63M$277.08M$378.27M$590.97M$419.27M
Current liabilities$78.06M$79.53M$53.32M$136.38M$51.79M
Long-term debt$51.36M$164.90M$213.16M$315.29M$313.46M
Total debt$51.36M$164.90M$213.16M$315.29M$313.46M
Total liabilities$446.86M$459.69M$403.25M$505.29M$395.49M
Shareholders' equity-$121.23M-$182.61M-$24.98M$85.68M$23.78M
Net debt$41.70M$161.50M$206.05M$304.28M$212.65M
Shares outstanding71.67M58.04M61.13M62.83M62.63M
Cash flow statement
Operating cash flow-$116.09M-$148.80M$74.73M-$86.48M-$109.72M
Capital expenditure$65,000$165,000$426,000$113,000$277,000
Free cash flow-$116.16M-$148.97M$74.30M-$86.60M-$110.00M
Investing cash flow$164.52M$82.22M$27.45M-$127.56M$193.71M
Financing cash flow-$42.17M$62.88M-$106.08M$124.25M$6.32M
Depreciation & amortization$964,000$950,000$920,000$952,000$1.39M
Stock-based compensation$8.19M$10.49M$11.65M$14.07M$17.63M
Share buybacks$0$11.85M$4.65M$0$0

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.